Navigation Links
Inhalable gene therapy may help pulmonary arterial hypertension patients
Date:7/30/2013

rcent of individuals have antecedent antibodies to the adeno-associated vectors, so potential patients need to be screened before gene therapy to make sure they are eligible to receive the vectors. In patients without antibodies, the restorative enzyme gene therapy does not cause an immune response, according to Dr. Hadri.

The clinical application of the gene therapy for patients with PAH will most likely differ from those with heart failure. The replacement gene needs to be injected through the coronary arteries of heart failure patients using catheters, while in PAH patients, the gene will need to be administered through inhalation.


'/>"/>

Contact: Lauren Woods
lauren.woods@mountsinai.org
212-241-2836
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
2. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
3. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
4. Immunotherapy for elderly cancer patients finds new promise in drug combination
5. Therapy exploits addiction of leukemia cells
6. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
7. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
8. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
9. 19th century therapy for Parkinsons disease may help patients today
10. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
11. Xenotransplantation as a therapy for type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 14, 2014 Recently, iFitDress.com, one of ... released its beautiful collection of brown evening dresses ... are now available at discounted prices, up to 50% ... of high quality; they are carefully made according to ... occasion gowns, iFitDress.com also offers pretty accessories: wedding shoes, ...
(Date:7/13/2014)... Dallas, TX (PRWEB) July 13, 2014 ... Roma vs. Real Madrid Tickets . For the fifth ... International Champions Cup will be held at American stadiums this ... world competing on American soil. The eight teams are split ... the group stage, the top two teams will compete to ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Chromatography ... biological components from various types of biological samples ... separate the sample mixture into two phase, namely ... the mobile phase run over the stationary phase, ... the components that provide the separation of mixture. ...
(Date:7/13/2014)... 13, 2014 The report “Micronutrient ... Iron), Form (Chelated & Non Chelated), Application Mode ... Global Trends and Forecast to 2018” defines and ... analysis and forecasting of the global value and ... driving and restraining factors for the global agriculture ...
(Date:7/13/2014)... York (PRWEB) July 13, 2014 A ... attention to the cancer risks associated with power morcellators ... tell their story to federal regulators, as they presented ... U.S. Food & Drug Administration (FDA) advisory panel meeting ... According to the Rochester Democrat and Chronicle, Dr. ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4
... Dynavax Technologies,Corporation (Nasdaq: DVAX ) today reported ... ended September 30, 2007. The results do not,include ... As of September 30, 2007, Dynavax reported ... Symphony Dynamo, Inc. (SDI),totaling $68.7 million. This compares ...
... global clinical,research organization, is pleased to announce that ... JCAHPO annual continuing education,program. Diana who designed an ... in ophthalmic practice for several years,prior to joining ... will take place in New Orleans, Louisiana from ...
... have for the first time found stem cells in ... such cells might someday be used to help repair ... , Reporting November 1, 2007 in the journal ... Irving Shapiro, Ph.D., at Jefferson Medical College of Thomas ...
... Video Component Enables Users to Upload Video Confessions/ ... on newfaceofresearch.com for Peer-to-Peer Viewing, PHILADELPHIA and ... Thomson Corporation (NYSE: TOC ; TSX: TOC) ... research and,business communities, today announced the launch of ...
... Spectrum,Pharmaceuticals, Inc., (Nasdaq: SPPI ) announced today ... Thursday, November 1, 2007, at 2:00 p.m.,Pacific, at the ... in San Diego, California. Spectrum,s presentation will be held ... The live webcast of Spectrum,s presentation will be available ...
... Health Inc.,(TSX: DAX) (Nasdaq: DRAX ) announces that ... he will retire as the President and Chief,Executive Officer ... Barkin joined the senior management of DRAXIS in 1992. ... guiding the Company through,a period of significant growth from ...
Cached Medicine News:Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 2Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 3Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 4Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 5Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 6Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 7Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 8Health News:Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook 9Health News:Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting 2Health News:Jefferson researchers find stem cells in degenerating spinal discs, potential for repair 2Health News:Thomson Scientific Launches 'Confessions ... of a User' Campaign Asking 'Are You the New Face of Research?' 2Health News:Spectrum Pharmaceuticals to Present at the 2007 BIOCOM Investor Conference 2Health News:DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer 2Health News:DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer 3Health News:DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer 4
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., ... services, has launched the FreeRunner™ knee brace with ... suffer from patella mal-tracking return to active lifestyles. ... than other braces, providing support when patients need ... when they don,t. Patellofemoral issues are ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... Md., March 27, 2007--A new study shows that ... the proportion of,cardiovascular disease (CVD) linked to diabetes ... for increased efforts to,prevent diabetes and to aggressively ... diabetes, according to the investigators,from the long-standing Framingham ...
... the year ended 31 December 2006 , Product ... Phase,III study International partnering process to commerialise M6G,underway ... Pharmaceuticals,plc ("CeNeS" or "the Company"), the CNS focused ... the year ended 31 December 2006. , Operational ...
Cached Medicine Technology:Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 2Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 3CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 2CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 3
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
ACMI™ Double-J Closed Tip Ureteral Stents feature patented dual durometer thermosensitive Tecoflex® construction for physician ease of placement and patient comfort....
Used for retrograde positioning of a ureteral stent. The radiopaque band improves fluoroscopic visibility of the positioner tip. Supplied sterile in peel-open packages. Intended for one-time use....
... for interoperative placement to stent ... construction and continent urinary diversions. ... Intended for one-time use. CAUTION: ... must not remain indwelling more ...
Medicine Products: